Chantix Update: FDA Evaluating Reports of Suicidal Thoughts In Chantix Users

On November 20, 2007, the Food and Drug Administration ("FDA") reported that it is evaluating post-marketing adverse event reports about Pfizer Inc.'s smoking cessation drug Chantix upon receiving company submitted reports about Chantix users having suicidal thoughts.

The FDA asked Pfizer for the reports. The FDA said that while it analyzed data, it recommends that health care providers monitor Chantix patients for behavior and mood changes. The FDA said patients should report behavior and mood changes to their doctors.

Claudine Q. Homolash, Esq. represents consumers who have been injured as a result of dangerous drugs and other products.